Interleukin-2-PE40
Latest Information Update: 14 Jul 1998
At a glance
- Originator German-Israeli Foundation for Scientific Research and Development
- Class Interleukins
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Transplant rejection
Most Recent Events
- 14 Jul 1998 No-Development-Reported for Autoimmune disorders in Germany (Unknown route)
- 14 Jul 1998 No-Development-Reported for Transplant rejection in Germany (Unknown route)
- 03 Nov 1994 Preclinical development for Autoimmune disorders in Germany (Unknown route)